Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab

BACKGROUND: Osimertinib has emerged as an important tool in the treatment of non-small cell lung cancers (NSCLC) with certain activating mutations of epidermal growth factor receptor (EGFR). However, Osimertinib may cause adverse effects, including severe cutaneous adverse reactions (SCARs) such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez, Michael, Hagopian, Garo, Doan, Linda, Lee, Benjamin J., Rojek, Nathan W., Smith, Janellen, Ou, Sai-Hong Ignatius, Demirdag, Yesim Yilmaz, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612162/
https://www.ncbi.nlm.nih.gov/pubmed/37898814
http://dx.doi.org/10.1186/s13223-023-00849-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612162/
https://www.ncbi.nlm.nih.gov/pubmed/37898814
http://dx.doi.org/10.1186/s13223-023-00849-5

Ejemplares similares